Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003

Executive Summary

FDA's effort to increase the rate that drug products are approved by their user fee goal date appears to be paying off, with significant improvement seen in 2003 compared to the year before

You may also be interested in...



First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?

FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS043062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel